Antiretroviral Agents in HIV-1 (2018)

Antiretroviral Agents in HIV-1 Pocket Guide

DHHS HIV GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/370315

Contents of this Issue

Navigation

Page 1 of 29

2 Selecting a Treatment Regimen Initiating Antiretroviral Therapy Î Antiretroviral therapy (ART) is recommended for all HIV-infected individuals, regardless of CD4 count, to reduce the morbidity and mortality associated with HIV infection (A-I). Î ART is also recommended for HIV-infected individuals to prevent transmission of HIV (A-I). Î When initiating ART, it is important to educate patients regarding the benefits and considerations of ART, and to address strategies to optimize adherence. • On a case-by-case basis, ART may be deferred because of clinical and/or psychosocial factors, but therapy should be initiated as soon as possible. What to Start: Initial Combination Regimens for the Antiretroviral-Naive Patient Î An antiretroviral (ARV) regimen for a treatment-naive patient generally consists of two nucleoside reverse transcriptase inhibitors (NRTIs) in combination with a third active ARV drug from one of three drug classes: an integrase strand transfer inhibitor (INSTI), a non- nucleoside reverse transcriptase inhibitor (NNRTI), or a protease inhibitor (PI) with a pharmacokinetic (PK) enhancer (booster) (cobicistat or ritonavir). Table 1a. Recommended Initial Regimens for Most People with HIV Recommended regimens are those with demonstrated durable virologic efficacy, favorable tolerability and toxicity profiles, and ease of use. INSTI + 2-NRTIs: Î BIC/TAF/FTC a (A-I) Î DTG/ABC/3TC a (A-I if HLA-B*5701 negative) Î DTG + tenofovir b /FTC a (A-I for both TAF/FTC and TDF/FTC) Î EVG/c/tenofovir b /FTC (A-I for both TAF/FTC and TDF/FTC) Î RAL c + tenofovir b /FTC a (A-I for TDF/FTC, A-II for TAF/FTC) a 3TC may be substituted for FTC, or vice versa, if a non–fixed-dose NRTI combination is desired. b TAF and TDF are two forms of tenofovir approved by the FDA. TAF has fewer bone and kidney toxicities than TDF, while TDF is associated with lower lipid levels. Safety, cost, and access are among the factors to consider when choosing between these drugs. c RAL can be given as 400 mg bid or 1200 mg (two 600-mg tablets) once daily.

Articles in this issue

Archives of this issue

view archives of Antiretroviral Agents in HIV-1 (2018) - Antiretroviral Agents in HIV-1 Pocket Guide